Tracers / [212Pb]Pb-MC1L
[212Pb]Pb-MC1L
Also written as [Pb-212]Pb-MC1L
- Radionuclide
- Pb-212 t½ 638.4 min
- Modality
- Therapy
- Production route
- —
- Stage
- —
- Syntheses indexed
- 4
What it is
- Compound class
- DOTA-conjugated cyclic peptide (melanocortin 1 receptor ligand)
- Target / mechanism
- Melanocortin 1 receptor (MC1R) PMID 31318566
- Clinical application
- Alpha-particle radioligand therapy for metastatic melanoma via MC1R targeting PMID 31318566
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | — | — | — | MC1L | 38095674 2024 Eur J Nucl Med Mol Imaging |
| — | — | — | — | — | MC1L | 38095674 2024 Eur J Nucl Med Mol Imaging |
| — | — | — | — | — | — | 37808634 2023 bioRxiv |
| Manual synthesis | — | HPLC | — | — | DOTA-MC1L | 31318566 2019 Mol Pharm 203PbCl2 was dissolved in 0.5 M HCl and 212PbCl2 eluted from 224Ra/212Pb generator |
Need this precursor?We can point you to suppliers for [212Pb]Pb-MC1L, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty.